Health related quality of life in chronic liver diseases.
chronic liver diseases
general population
health-related quality of life
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
13
05
2020
revised:
03
08
2020
accepted:
16
08
2020
pubmed:
28
8
2020
medline:
22
6
2021
entrez:
28
8
2020
Statut:
ppublish
Résumé
The impact of chronic liver diseases (CLDs) on health-related quality of life (HRQoL) is relevant to understand the burden of these conditions and inform decision-making processes related to their care. Studies simultaneously comparing the HRQoL of patients affected by the major CLDs to that of the general population are still lacking and are the subject of this study. Using the EQ-5D-3L questionnaire, we analysed and compared HRQoL data from 2962 Italian patients affected by CLDs and forming a representative sample of the general Italian population (6800 individuals). Exploratory analyses were conducted to investigate the effects of each CLD on HRQoL, using the general population as reference and adjusting for possible confounders. Patients with CLDs (HBV, HCV, PSC, PBC, AIH, NAFLD/NASH) in the chronic hepatitis stage and with compensated cirrhosis (CC) showed HRQoL similar to the general population. However, AIH were more likely to report problems in self-care and lower EQ-5D VAS score, while NAFLD/NASH and HCV showed an increased risk of anxiety/depression. On the other hand, with progression to more advanced stages of liver disease (DC or HCC), HRQoL decreased significantly with higher risk of reporting problems in the physical domains, and significant reductions in the VAS and utility index scores. Different subtypes of CLD affected different QoL domains. This study therefore provides a real estimate of the impact of CLDs on patients' HRQoL, and represents a much needed tool to inform decision-making while assessing the effectiveness and cost-effectiveness of the care of these patients.
Sections du résumé
BACKGROUND & AIMS
The impact of chronic liver diseases (CLDs) on health-related quality of life (HRQoL) is relevant to understand the burden of these conditions and inform decision-making processes related to their care. Studies simultaneously comparing the HRQoL of patients affected by the major CLDs to that of the general population are still lacking and are the subject of this study.
METHODS
Using the EQ-5D-3L questionnaire, we analysed and compared HRQoL data from 2962 Italian patients affected by CLDs and forming a representative sample of the general Italian population (6800 individuals). Exploratory analyses were conducted to investigate the effects of each CLD on HRQoL, using the general population as reference and adjusting for possible confounders.
RESULTS
Patients with CLDs (HBV, HCV, PSC, PBC, AIH, NAFLD/NASH) in the chronic hepatitis stage and with compensated cirrhosis (CC) showed HRQoL similar to the general population. However, AIH were more likely to report problems in self-care and lower EQ-5D VAS score, while NAFLD/NASH and HCV showed an increased risk of anxiety/depression. On the other hand, with progression to more advanced stages of liver disease (DC or HCC), HRQoL decreased significantly with higher risk of reporting problems in the physical domains, and significant reductions in the VAS and utility index scores.
CONCLUSIONS
Different subtypes of CLD affected different QoL domains. This study therefore provides a real estimate of the impact of CLDs on patients' HRQoL, and represents a much needed tool to inform decision-making while assessing the effectiveness and cost-effectiveness of the care of these patients.
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2630-2642Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Scalone L, Fagiuoli S, Ciampichini R, et al. The societal burden of chronic liver diseases: results from the COME study. BMJ Open Gastroenterol. 2015;2:e000025.
Wong LL, Fisher HF, Stocken DD, et al. The impact of autoimmune hepatitis and its treatment on health utility. Hepatology. 2018;68:1487-1497.
Orr JG, Homer T, Ternent L, et al. Health related quality of life in people with advanced chronic liver disease. J Hepatol. 2014;61:1158-1165.
McLernon DJ, Dillon J, Donnan PT. Health-state utilities in liver disease: a systematic review. Med Decis Making. 2008;28:582-592.
Mells GF, Pells G, Newton JL, et al. Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study. Hepatology. 2013;58:273-283.
Schramm C, Wahl I, Weiler-Normann C, et al. Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis. J Hepatol. 2014;60:618-624.
Sayiner M, Stepanova M, Pham H, et al. Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease. BMJ Open Gastroenterol. 2016;3:e000106.
Hsu PC, Federico CA, Krajden M, et al. Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. J Gastroenterol Hepatol. 2012;27:149-157.
Ong SC, Mak B, Aung MO, et al. Health-related quality of life in chronic hepatitis B patients. Hepatology. 2008;47:1108-1117.
Björnsson E, Verbaan H, Oksanen A, et al. Health-related quality of life in patients with different stages of liver disease induced by hepatitis C. Scand J Gastroenterol. 2009;44:878-887.
Gutteling JJ, de Man RA, Busschbach JJ, et al. Overview of research on health-related quality of life in patients with chronic liver disease. Neth J Med. 2007;65:227-234.
Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med. 1993;118:622-629.
McTaggart-Cowan HM, Marra CA, Yang Y, et al. The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control status. Qual Life Res. 2008;17:453-462.
EuroQol Group. EQ-5D instrument. https://euroqol.org/eq-5d-instruments/. Accessed April 17, 2020.
NICE. Guide to the Methods of Technology Appraisal 2013: Process and Methods Guides. London: National Institute of Health and Care Excellence; 2013.
Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337-343.
Mantovani LG, Cortesi PA, Strazzabosco M. Effective but costly: how to tackle difficult trade-offs in evaluating health improving technologies in liver diseases. Hepatology. 2016;64:1331-1342.
Carbone M, Cristoferi L, Cortesi PA, et al. Optimising the clinical strategy for autoimmune liver diseases: principles of value-based medicine. Biochim Biophys Acta. 2018;1864:1415-1422.
Strazzabosco M, Cortesi PA, Conti S, et al. Clinical outcome indicators in chronic hepatitis B and C: a primer for value-based medicine in hepatology. Liver Int. 2020;40:60-73.
Scalone L, Cortesi PA, Ciampichini R, Cesana G, Mantovani LG. Health Related Quality of Life norm data of the Italian general population: results using the EQ-5D-3L and EQ-5D-5L instruments. Epidemiol Biostat Public Health. 2015;12:e11457-1-e11457-15.
Strazzabosco M, Allen JI, Teisberg EO. Value based care in hepatology. Hepatology. 2017;65:1749-1755.
Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646-649.
Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-1917.
Scalone L, Cortesi PA, Ciampichini R, et al. Italian population-based values of EQ-5D health states. Value Health. 2013;16:814-822.
Austin PC. A comparison of methods for analyzing health-related quality-of-life measures. Value Health. 2002;5:329-337.
Vietri J, Prajapati G, El Khoury AC. The burden of hepatitis C in Europe from the patients' perspective: a survey in 5 countries. BMC Gastroenterol. 2013;13:16.
El Khoury AC, Vietri J, Prajapati G. Health-related quality of life in patients with hepatitis C virus infection in Brazil. Rev Panam Salud Publica. 2014;35:200-206.
Younossi Z, Henry L. Systematic review: patient-reported outcomes in chronic hepatitis C-the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther. 2015;41:497-520.
Brazier J, Ratcliffe J, Salomon J, Tsuchiya A. Measuring and Valuing Health Benefits for Economic Evaluation - Second Edition. Oxford, UK: Oxford University Press. https://doi.org/10.1093/med/9780198725923.001.0001
Golabi P, Otgonsuren M, Cable R, et al. Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL). Health Qual Life Outcomes. 2016;14:18.
Haapamäki J, Tenca A, Sintonen H, et al. Health-related quality of life among patients with primary sclerosing cholangitis. Liver Int. 2015;35:2194-2201.
Newton JL, Bhala N, Burt J, et al. Characterisation of the associations and impact of symptoms in primary biliary cirrhosis using a disease specific quality of life measure. J Hepatol. 2006;44:776-783.
Wai CT, Mak B, Chua W, et al. The majority of hepatitis B carriers are not on regular surveillance in Singapore. Singapore Med J. 2004;45:423-426.
Wang C, Chen V, Vu V, et al. Poor adherence and low persistency rates for hepatocellular carcinoma surveillance in patients with chronic hepatitis B. Medicine (Baltimore). 2016;95:e4744.
EuroQol group. https://euroqol.org/eq-5d-instruments/eq-5d-3l-available-modes-of-administration/telephone-interview-version/. Accessed July 16, 2020.
Brooks R. The EuroQol Group after 25 years. Heidelberg, Germany: Springer Science & Business Media; 2012.
Brazier J, Jones N, Kind P. Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual Life Res. 1993;2:169-180.
Lins L, Carvalho FM. SF-36 total score as a single measure of health-related quality of life: scoping review. SAGE Open Med. 2016;4:2050312116671725.
Bharmal M, Thomas J 3rd. Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population. Value Health. 2006;9:262-271.
Rabin R, Gudex C, Selai C, Herdman M. From translation to version management: a history and review of methods for the cultural adaptation of the EuroQol five-dimensional questionnaire. Value Health. 2014;17:70-76.